Shots:
- Health Canada has granted authorization under interim order for the emergency use of BNT162b2. The distribution of the vaccine in Canada will be prioritized according to the populations identified in guidance from the NACI
- BioNTech will hold the regulatory approval in Canada while Pfizer will have the commercialization rights. The approval is based on data that was filed through the rolling submission regulatory pathway and data from the P-l/ll clinical trial that began recruiting in Jul’2020 & enrolled ~44,000 patients across ~150 sites in multiple countries
- The companies will supply ~20M doses of vaccine to Canada through 2021
Click here to read full press release/ article | Ref: PRNewswire | Image: Bloomberg Quint
The post Pfizer and BioNTech ‘s BNT162b2 Receive Health Canada Authorization to Combat COVID-19 first appeared on PharmaShots.
